Table 1.
Patient Characteristics
| Characteristic | Explanted aortic valves |
|---|---|
| Patients | 52 |
| Male sex | 38 (73) |
| Age, years | 70 (45–87) |
| AVA, cm2 | 0.8 (0.4–1.1) |
| AVA/BSA, cm2/m2 | 0.38 (0.2–0.63) |
| P-max, mmHg | 76 (42–125) |
| P-mean, mmHg | 47 (22–69) |
| LVEF, % | 60 (30–79) |
| LVEDD, mm | 45 (35–68) |
| Comorbidities | |
| Diabetes mellitus | 13 (25) |
| Presence of obstructive coronary artery disease | 23 (44.2) |
| Hyperlipidemia | 38 (73) |
| Hypertension | 40 (76.9) |
| Renal dysfunction | 4 (7.7) |
| Serum creatinine, μmol/L | 84.86 (47.73–646.2) |
| Smoker status | |
| Current | 1 (1.92) |
| No smoker | 28 (53.8) |
| Former | 23 (44.2) |
| HbA1c, % | 5.75 (4.8–12) |
| Medication | |
| Acetylsalicylic acid | 36 (69.2) |
| Angiotensin receptor blockade | 10 (19.2) |
| ACE inhibitor | 19 (36.5) |
| β-Blocker | 26 (50) |
| Statin | 37 (71.1) |
| Ca-antagonist | 11 (21.1) |
Values are n (%) or median (range).
ACE, angiotensin-converting enzyme; AVA, aortic valve area; AVA/BSA, aortic valve area, indexed for body surface area; LVEF, left ventricle ejection fraction; HbA1c, glycated hemoglobin; LVEDD, left ventricular end-diastolic diameter; P-max, maximal transvalvular pressure; P-mean, mean transvalvular pressure.